Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study

Barsotti, Simone; Cavazzana, Ilaria; Zanframundo, Giovanni; Neri, R; Taraborelli, Mara; Cioffi, Elisa; Cardelli, Chiara; Tripoli, Alessandra; Codullo, Veronica; Tincani, Anǵela; Cavagna, Lorenzo; Franceschini, Franco; Mosca, Marta

doi:10.1016/j.autrev.2021.102757

Cited by 7 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study from Sweden observed that 82% of the IBM patients ever tried immunomodulating treatment [ 61 ]. Nevertheless, there is yet no international consensus on the effectiveness of IVIg treatment in IBM, although positive treatment responses are observed [ 13 , 62 ]. In addition, inconsistent cost coverage of IVIg depending on health system and health insurance could increase uncertainties that promote practice variations in routine clinical practice and heterogenous patient outcomes.…”

Section: Discussionmentioning

confidence: 99%

Cost of illness in inclusion body myositis: results from a cross-sectional study in Germany

Senn,

Thiele,

Kummer

et al. 2023

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background Inclusion body myositis (IBM) is the most frequent type of myositis in elder patients with a slow chronic progression and refractory to treatment. Previous cost of illness (COI) studies in IBM used claims data to estimate direct costs in the US. No evidence exists globally on both direct and indirect costs in IBM from a societal perspective. We conducted a survey in patients registered in the German IBM patient registry. Self-developed items were used to assess the utilized healthcare resources and estimate the cost. The German Self-Administered Comorbidity Questionnaire (SCQ-D), the sIBM Physical Functioning Assessment (sIFA) and patient-reported measures for satisfaction and improvements in healthcare were applied for an explorative analysis. Results In total, 82 patients completed the survey. We estimated the mean total annual per capita COI of US$102,682 (95% CI US$82,763–US$123,090) in 2021. 92.7% of the total COI were direct costs. Medical costs were similar to nonmedical costs, with substantial costs for pharmacotherapy and informal care. Depending on the prevalence estimate, the total national COI per year were US$42.7 million–US$213.7 million. Significant differences in total COI were identified for the degree of disability, marital and employment status (p < 0.05). Conclusions We identified remarkable and heterogenous cost in IBM. As informal care costs represented the most relevant cost driver, caregiver burden is a major factor in the patient journey. For the first time, comprehensive economic potentials were identified as a basis to improve the actual care situations and prioritizing future activities for research, pharmaceutical and digital product development as well as health politics.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost of illness in inclusion body myositis: results from a cross-sectional study in Germany

Senn,

Thiele,

Kummer

et al. 2023

Orphanet J Rare Dis

View full text Add to dashboard Cite

show abstract

“…Barsotti et al used IVIg to treat 123 IIM patients with active steroid-resistant myositis and/or for contraindication to immunosuppressive treatment. A total of 71-82% of the patients were noted to demonstrate a subjective improvement in dysphagia and a significant decrease in Visual Analogue Scale (VAS) scores[101]. In a study conducted by Giannini et al, 12 patients with IIM-related dysphagia who had not responded to high-dose glucocorticoids with methotrexate or azathioprine showed a progressive improvement of FEES abnormalities and the reduction in EAT-10 scores at 52 weeks of follow up[102].…”

mentioning

confidence: 99%

Autoimmune Dysphagia Related to Rheumatologic Disorders: A Focused Review on Diagnosis and Treatment

Shaik¹,

Shaik²,

Mikdashi³

2023

Cureus

View full text Add to dashboard Cite

Autoimmune dysphagia is defined as dysphagia caused by autoimmune processes affecting various components of the swallowing process such as muscle, neuromuscular junction, nerves, roots, brainstem, or cortex. These autoimmune causes can be classified into gastroenterological, dermatological, rheumatologic, and neurologic. Rheumatological disorders, such as scleroderma, Sjogren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis, Behcet's disease, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, or granulomatosis with polyangiitis, have been associated with dysphagia. Autoimmune dysphagia in the context of rheumatological disorders is particularly significant because it can occur as a sole manifestation or as part of a symptom complex associated with the underlying disorder and often responds to immunosuppressive therapies. However, diagnosing autoimmune dysphagia can be challenging as it requires the exclusion of structural and primary motility disorders through procedures such as endoscopy and manometry. Early diagnosis is important to improve the quality of life and prevent significant mortality and morbidity. Management focuses on treating the underlying disease activity, and a multidisciplinary approach involving various medical specialties may be necessary to achieve success. This article aims to review the autoimmune rheumatological conditions that can lead to dysphagia and discuss the associated pathophysiological mechanisms. We also outline the clinical clues and laboratory testing methods that facilitate early diagnosis, with the goal of improving patient outcomes through timely intervention and appropriate management.

show abstract

Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use

et al. 2023

View full text Add to dashboard Cite

Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study

Cited by 7 publications

References 29 publications

Cost of illness in inclusion body myositis: results from a cross-sectional study in Germany

Cost of illness in inclusion body myositis: results from a cross-sectional study in Germany

Autoimmune Dysphagia Related to Rheumatologic Disorders: A Focused Review on Diagnosis and Treatment

Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use

Contact Info

Product

Resources

About